CSIMarket Company Name, Ticker, Customers, else..
 
Tectonic Therapeutic Inc   (NASDAQ: TECX)
 
Price: $27.4600 $-0.45 -1.612%
Day's High: $28.709999084472656 Week Perf: -5.47 %
Day's Low: $ 27.13 30 Day Perf: -24.99 %
Volume (M): 83,430 52 Wk High: $ 39.53
Volume (M$): $ 0 52 Wk Avg: $25.63
Open: $28.15 52 Wk Low: $14.39



 Market Capitalization (Millions $) 521
 Shares Outstanding (Millions) 19
 Employees 60
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -86
 Cash Flow (TTM) (Millions $) -51
 Capital Exp. (TTM) (Millions $) 0

Business Description


Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of therapeutic proteins and antibodies that target G-protein coupled receptors (GPCRs). The company utilizes a proprietary technology platform, GEODe™, to develop GPCR-targeted biologic medicines for medical conditions with limited or no existing therapeutic options.


   Company Address: 490 Arsenal Way Watertown 2472 MA
   Company Phone Number: 666-3320   Stock Exchange / Ticker: NASDAQ TECX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ATRA   -3.94%    
DNA        15.34% 
IMCR   -4.91%    
KRYS   -2.36%    
PLX   -1.65%    
RGNX   -5.26%    
• View Complete Report
   



Clinical Study

Tectonic Therapeutics TX45 Shows Promise in Managing Group 2 Pulmonary Hypertension Amidst Market Speculation

Published Sun, May 18 2025 11:00 AM UTC

Tectonic Therapeutic, Inc. (NASDAQ: TECX) recently shared the complete results from Part A of their Phase 1b clinical trial of TX45, a potential treatment for Group 2 Pulmonary Hypertension in patients with Heart Failure with preserved Ejection Fraction (HFpEF). These results, which represent a significant milestone for Tectonic s leading asset a long-acting relaxin therapy ...
Product Service News

On November 11, 2024, Tectonic Therapeutics, a clinical-stage biotechnology firm based in Watertown, Massac...

Published Mon, Nov 11 2024 10:00 AM UTC

Tectonic Therapeutics Makes Strides in Heart Failure Treatment with Promising TX45 Phase 1a Results On November 11, 2024, Tectonic Therapeutics, a clinical-stage biotechnology firm based in Watertown, Massachusetts, unveiled positive results from a Phase 1a trial for its lead therapeutic candidate, TX45. This innovative drug, formulated as a long-acting Fc-relaxin fusion pro...
Clinical Study

TX45 Moves Forward with Strong Phase 1a Results Safety, Tolerability, and Robust PK/PD Data Fuel Phase 2 Readin...

Published Thu, Sep 19 2024 8:01 PM UTC

Tectonic Therapeutics, a clinical-stage biotechnology company, recently announced positive outcomes from the Phase 1a clinical trial of its lead investigational drug, TX45. The results underscore the drug s potential, showing a robust safety profile, absence of immunogenicity, and a favorable pharmacokinetic/pharmacodynamic (PK/PD) relationship. These findings have been inst...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 2.33
PEG (TTM) -

Financial Strength Current
Quick Ratio 15.96
Working Capital Ratio 16.25
Leverage Ratio (MRQ) 0.08
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -4047.53 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 11.97 $
Book Value 11.8 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,429,783
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.